ProteoGenix Announces a COVID-19 Antibody Library

ProteoGenix has announced the first Human Immune COVID-19 library for the fast discovery of potent antibodies against SARS-CoV-2.

"Highly sensitive and specific antibodies are critical for the development of diagnostics, therapeutics, and prophylactics to fight against COVID-19," said Philippe Funfrock, Co-founder and President of ProteoGenix. "The new Human Immune COVID-19 antibody library developed by ProteoGenix represents an exciting opportunity to solve the current pandemic."

The library, created using blood samples from dozens of recovered COVID-19 patients, is adapted for screening with phage display and strives to meet the rising demands for effective antibodies for a broad range of applications.

The library’s vast diversity (1.2 x 1010 different clones) allied to the fast turnaround time and sensitivity of the screening technology, are intended to fast-track the discovery of antibodies with the strongest affinity, specificity, and viral blocking activity.

"Compared to the hybridoma technology, phage display saves time by allowing us to directly screen highly diverse and human antibody libraries. In addition, when developing therapeutic antibodies, this technique also helps us reduce the time-to-market by avoiding complex antibody humanization processes," said Raphaël Hopfner, Co-founder and CSO of ProteoGenix.

ProteoGenix further fast-tracks the process of discovery by offering a broad diversity of ready-made SARS-CoV-2 antigens, as well as fast custom antigen development services (proteins, peptides, small molecules).

Within 8 weeks or less, clients can receive 3 to 10 unique and royalty-free antibody sequences with an optimal affinity. Being the first to propose this service, ProteoGenix aims at supporting the outstanding efforts of teams fighting the COVID-19 pandemic around the world.

CPhI China 2020 To Be Postponed to Dec. 16-18th,

Register as Visitor to the 20th Edition of CPhI China!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.